Could a diabetes drug and a blood pressure pill shield vasculitis patients from heart attacks?
NCT ID NCT06887062
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study looks at whether two medications, dapagliflozin (a diabetes drug) and bosentan (a blood pressure drug), can improve blood vessel health in people with large vessel vasculitis (LVV). LVV causes blood vessel damage and raises the risk of heart attacks and strokes. The trial will give 60 participants with stable LVV both drugs for 6 weeks, then dapagliflozin alone for 4 weeks, and measure changes in blood vessel function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Edinburgh
RECRUITINGEdinburgh, EH16 4TJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.